Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer

Chinese Journal of Cancer

Volumn 31, Issue 10, 2012, Pages 491-499

  Zhang, Lan Jun ^a   Cai, Ling ^a   Li, Zhe ^a   Wang, Wu Ping ^b   Guo, Kang ^a   Shao, Jian Yong ^a   Wang, Jun Ye ^a   Yu, Hui ^a   Rong, Tie Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Correlation; Epidermal growth factor receptor; Gene copy number; Gene mutation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; ONCOLOGICAL PARAMETERS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84867560890     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10409     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011,61:69-90.
2. Dahabreh IJ, Linardou H, Siannis F, et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-sm all cell lung cancer. Clin Cancer Res, 2010,16:291-303.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-in stitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-sm all-ce ll lung cancer (the IDEAL 1 Trial). J Clin Oncol, 2003,21:2237-2246.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-sm all cell lung cancer: a randomized trial. JAMA, 2003,290:2149-2158.
5. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-sm all-ce ll lung cancer. J Clin Oncol, 2004,22: 1103-1109.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004,304:1497-1500.
7. Chen C, Jiang XL, Zhang CC, et al. Correlation of genes associated with drug response to prognosis of large cell lung carcinoma. Chin J Cancer, 2011,30:497-504.
8. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-sm all cell lung cancer. Clin Cancer Res, 2006,12:7232-7241.
9. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med, 2005,353:133-144.
10. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-ce ll lung cancer. J Natl Cancer Inst, 2005,97:643-655.
11. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-sm all cell lung carcinoma. Am J Clin Pathol, 2006,125:860-865.
12. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-sm all-ce ll lung cancer. J Clin Oncol, 2007,25:587-595.
13. Chang JW, Liu HP, Hsieh MH, et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer, 2008,61:328-339.
14. Helfrich BA, Raben D, Varella-G arcia M, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, iressa) in non-sm all cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res, 2006,12:7117-7125.
15. Dziadziuszko R, Hirsch FR, Varella-G arcia M, et al. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization why, when, and how? Clin Cancer Res, 2006,12:4409s-4415s.
16. Cappuzzo F. EGFR fish versus mutation: different tests, different end-po ints. Lung Cancer, 2008,60:160-165.
17. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2007,2:706-714.
18. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-sm all-cell lung cancer. Clin Cancer Res, 2006,12:3915-3921.
19. Morgensztern D, Govindan R. Lung cancer: a clinical guide. Baltimore, MD: Lippincott William & Wilkins, 2008.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-sm all-ce ll lung cancer to gefitinib. N Engl J Med, 2004,350:2129-2139.
21. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008,26:4268-4275.
22. Hirsch FR, Varella-G arcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-sm all-ce ll lung cancer. J Clin Oncol, 2006,24:5034-5042.
23. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004,64:8919-8923.
24. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 2004,101:13306-13311.
25. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinico-pathologic features in non-sm all cell lung cancers. Clin Cancer Res, 2005,11:1167-1173.
26. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-sm all-ce ll lung cancer. J Clin Oncol, 2005,23:6829-6837.
27. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-sm all-ce ll lung cancer: molecular analysis of the ideal/intact gefitinib trials. J Clin Oncol, 2005,23:8081-8092.
28. Liang Z, Zhang J, Zeng X, et al. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer, 2010,10:376.
29. Liu H, Li Y, Chen G, et al. Detection and its clinical significance of EGFR gene mutation and gene amplification in 187 patients with non-sm all cell lung cancer. Zhongguo Fei Ai Za Zhi, 2009,12:1219-1228. [in Chinese]
30. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-po sitive/phospho-ak t-po sitive or never smoker patients with advanced non-sm all-ce ll lung cancer: the oncobell trial. J Clin Oncol, 2007,25:2248-2255.
31. Hirsch FR, Varella-G arcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol, 2005,23:6838-6845.
32. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One, 2009,4:e7464.
33. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-m utated lung cancer. Cancer Res, 2008,68:2106-2111.
34. Soh J, Toyooka S, Ichihara S, et al. Sequential molecular 35 changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol, 2008,3:340-347.
35. Casorzo L, Corigliano M, Ferrero P, et al. Evaluation of 7q31 region improves the accuracy of EGFR fish assay in non small cell lung cancer. Diagn Pathol, 2009,4:36.